CDC25A抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue lysate, Primary antibody: P07179(CDC25A Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07179(CDC25A Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

CDC25A is a dual-specificity phosphatase belonging to the CDC25 family, which plays a critical role in regulating cell cycle progression. It primarily activates cyclin-dependent kinases (CDKs) by removing inhibitory phosphorylations, thereby driving transitions through the G1/S and G2/M checkpoints. Overexpression or dysregulation of CDC25A is linked to uncontrolled cell proliferation, genomic instability, and tumorigenesis, making it a biomarker of interest in cancers such as breast, lung, and colorectal malignancies.

Antibodies targeting CDC25A are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to quantify protein levels or assess subcellular distribution. High-quality CDC25A antibodies are typically validated for specificity using knockout (KO) cell lines or siRNA-mediated knockdown to minimize cross-reactivity with homologous family members (e.g., CDC25B/C). Species reactivity often includes human, mouse, and rat samples.

In cancer research, CDC25A antibodies help evaluate its prognostic significance and therapeutic potential. Small-molecule inhibitors targeting CDC25A are under investigation, and these antibodies aid in mechanistic studies of drug efficacy. Challenges include distinguishing post-translational modifications (e.g., phosphorylation) that regulate CDC25A stability during DNA damage responses. Researchers must optimize experimental conditions to account for such dynamic changes, ensuring accurate interpretation of CDC25A-related pathways in health and disease.